Navigation Links
Pegloticase BLA Filing Accepted for Priority Review by FDA
Date:12/29/2008

Application for Treatment-Failure Gout Granted Priority Review

EAST BRUNSWICK, N.J., Dec. 29 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients. The FDA also granted the Company's BLA with a priority review status which accelerates the review period to six months. A priority review designation is assigned to drugs that are deemed by the FDA to have the potential to provide an important advancement in treatment or provide a treatment for which there is no adequate therapy available. Under priority review, the target date for an FDA decision on the pegloticase BLA is April 30, 2009.

The BLA submission is based on the two replicate, six-month Phase 3 clinical trials, performed under the auspices of a special protocol assessment. Additionally, the Company's BLA includes data from the open label extension (OLE) study for pegloticase, per the request of the FDA. The OLE study allowed those patients who completed the Phase 3 trials to continue or begin receiving pegloticase for an extended period of time. The data set includes 101 patients with at least twelve months of continuous treatment. Pegloticase was previously granted orphan drug designation by the FDA.

Treatment-failure gout occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with allopurinol at the maximum medically appropriate dose or for whom allopurinol is contraindicated.

ABOUT PEGLOTICASE

Pegloticase (formerly referred to as Puricase(R)) is a pegylated recombinant mammalian urate oxidase in development to contr
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
2. Barrs BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA
3. Accuray Receives Nasdaq Notification Related to the Late Filing of Form 10-Q
4. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
5. Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer
6. KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q
7. Corporate Parent Hospital Partners of America Files Voluntary Chapter 11 Petition; Filings do not Include any Hospital Facilities
8. VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment
9. Wound Management Technologies, Inc. Announces Filing of a 510K
10. Digestive Care, Inc. Announces the Filing of the First Module of NDA Submission for PANCRECARB(R) (pancrelipase)
11. Statement Regarding the Filing of Signatures to Put the Human Embryo Stem Cell Issue on the November Statewide Ballot
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... SCI explores disability in ... systemic barriers for disabled athletes with Aaron Scheidies ... a condition called juvenile macular degeneration, where he loses ... adapted his athletic ambitions to his vision and how ... to pioneer the way for other blind and visually ...
(Date:12/21/2014)... December 21, 2014 The Oncology Institute of ... the Santa Ana and Whittier offices. The Hope for the ... lives of patients and their families during the holiday season. ... to approximately 70 children between both offices. This event continues ... of Target’s community service team, store managers and assistant managers ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just ... has drastically cut prices to all its prom dresses ... 30, 2015. Many of the hottest styles are sold ... dresses, and more. , A spokesman for MissyDress says, ... A-line princess prom dresses or sweetheart chiffon prom dresses, ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 ... that allege a metal-on-metal version of the artificial ... forward in state and federal courts, Bernstein Liebhard ... New Jersey’ Bergen County Superior Court on December ... permitted to begin deposition of plaintiffs on November ...
(Date:12/20/2014)... 2014 The Doctor’s Office Urgent Care of ... part of a decade. They’ve treated over 40,000 patients ... healthcare alternative to the Paramus area. , ... additions to their staff of top-notch board certified physicians: Christine ... These new doctors will work tirelessly to carry ...
Breaking Medicine News(10 mins):Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2
... Gardner HealthDay Reporter , WEDNESDAY, April 11 ... "body clock" rhythms, could result in some of the ... obesity and diabetes, researchers report. Participants in the ... six hours a night and who were subjected to ...
... with family members, friends, and neighbors -- can lead ... in some cases it may actually be an obstacle ... investigators at Dana-Farber Cancer Institute and the Harvard School ... researchers theorize that for people made vulnerable by low ...
... 11 (HealthDay News) -- Treatment-related complications are common in ... completed, a new study says. Researchers looked at ... than 60 percent of them had at least one ... and 30 percent had at least two complications. ...
... for breast cancer can experience cognitive declines, such as ... Often experienced by patients undergoing chemotherapy, the declines have ... at the University of Missouri says "chemo brain" isn,t ... and chair of the Health Psychology Department in the ...
... News) -- An experimental drug reversed many of the ... report. Fragile X syndrome is a leading cause ... learning and memory difficulties, low IQ, seizures and social ... mGlu5, a receptor for a neurotransmitter known as glutamate, ...
... Sciences Discovery Fund (LSDF) today announced nearly $450,000 ... foster commercial translation of new health and health-care ... disease. Dr. Philip Fleckman at the University of ... material for reducing infections associated with kidney dialysis ...
Cached Medicine News:Health News:Disrupted Sleep May Raise Risk for Obesity, Diabetes: Study 2Health News:Disrupted Sleep May Raise Risk for Obesity, Diabetes: Study 3Health News:Social ties have mixed impact on encouraging healthy behaviors in low-income areas 2Health News:Breast Cancer Treatment Side Effects May Last for Years 2Health News:Stress contributes to cognitive declines in women with breast cancer, researcher says 2Health News:In Mice, Drug Reverses Symptoms of Condition Linked to Autism 2Health News:Washington's Life Sciences Discovery Fund awards commercialization grants 2
(Date:12/17/2014)...  Northstar Global Business Services, Inc. (OTCPink:MDIN) today ... made their final decision and has determined to ... effective December 15, 2014, and has resumed accepting ... book entry transfer services. All deposit restrictions have been ... fully "DTC Eligible", and has resumed electronic trading ...
(Date:12/17/2014)... 2014  Beamz Interactive, Inc. (OTCQB: BZIC), a ... announced that it has signed an agreement with ... of innovative prosthetic, orthotic and assistive technology products ... agreement, RSL Steeper will promote and supply the ... use within UK residential care facilities through its ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Consulting, a business unit of PAREXEL International (Nasdaq: ... serving the biopharmaceutical and medical device industries, today released ... provide key insights into emerging areas of biosimilar development. ... Consultant and Cecil Nick, B.Sc. (Hons), Vice President, Biotechnology, ...
... of Primary Astrocytes With Anti-GLAST MicroBeads -- BERGISCH GLADBACH, Germany, September 22, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers 2PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers 3PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers 4PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers 5Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 2Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 3Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 4Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 5Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 6
The ISI Digi Grip has the strength needed for secure ,upper extremity traction....
The ApexPro CH is operational within the WMTS. It offers operating performance, up to 240 WMTS channels, and up to 120 hours of battery life....
... portable TeleMon companion monitor, and IntelliVue ... and monitoring solution for ambulating patients ... and SpO2. Clinicians can get access ... from the central station, monitoring cockpit, ...
ISI DuraHand is the reusable, easy to sterilize surgical hand immobilizer....
Medicine Products: